Meeting
2023 ASCO Annual Meeting
Phase II trial of split-dose R-CHOP for older patients with diffuse large B-cell lymphoma (DLBCL).
Authors
Nirav Niranjan Shah
Medical College of Wisconsin, Milwaukee, WI
Nirav Niranjan Shah , Aniko Szabo , Saurabh Rajguru , Sumana Devata , Mitch Howard , Deepa Pereira , Mariah Endres , Walter L. Longo , Mehdi Hamadani , Timothy S. Fenske , Christopher David Fletcher
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT03943901
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7554)
DOI
10.1200/JCO.2023.41.16_suppl.7554
Abstract #
7554
Poster Bd #
105
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.
First Author: Bei Hu
Poster
2023 ASCO Annual Meeting
Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study.
First Author: Michael Dickinson
Poster
2022 ASCO Annual Meeting
Long-term outcomes and circulating tumor DNA analysis from a phase I/II study of lenalidomide and obinutuzumab with CHOP for newly diagnosed diffuse large B-cell lymphoma.
First Author: Hua-Jay Jeffery Cherng
Poster
2012 ASCO Annual Meeting
Determinants of and outcomes associated with chemoimmunotherapy dose density in elderly subjects with diffuse large B-cell lymphoma (DLBCL).
First Author: Usha S. Perepu